1
|
Mookkan M, Kandasamy S, Al-Odayni AB, Abduh NAY, Srinivasan S, Revannasidappa BC, Kumar V, Chinnasamy K, Aravindhan S, Shankar MK. A Structural and In Silico Investigation of Potential CDC7 Kinase Enzyme Inhibitors. ACS OMEGA 2023; 8:47187-47200. [PMID: 38107948 PMCID: PMC10719926 DOI: 10.1021/acsomega.3c07059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 11/13/2023] [Accepted: 11/16/2023] [Indexed: 12/19/2023]
Abstract
A crucial role in the regulation of DNA replication is played by the highly conserved CDC kinase. The CDC7 kinase could serve as a target for therapeutic intervention in cancer. The primary heterocyclic substance is pyrazole, and its derivatives offer great potential as treatments for cancer cell lines. Here, we synthesized the two pyrazole derivatives: 4-(2-(4-chlorophenyl)hydrazinyl)-5-methyl-2-tosyl-1H-pyrazol-3(2H)-one (PYRA-1) and 4-(2-(2,4-difluorophenyl)hydrazinyl)-5-methyl-2-tosyl-1H-pyrazol-3(2H)-one (PYRA-2). The structural confirmation of both the compounds at the three-dimensional level is characterized using single crystal X-ray diffraction and density functional theory. Furthermore, the in silico chemical biological properties were derived using molecular docking and molecular dynamics (MD) simulations. PYRA-1 and PYRA-2 crystallize in the P-1 (a = 8.184(9), b = 14.251(13), c = 15.601(15), α = 91.57(8), β = 97.48(9), 92.67(9), V = 1801.1(3) 3, and Z = 2) and P21/n (a = 14.8648(8), b = 8.5998(4), c = 15.5586(8), β = 116.47(7), V = 1780.4(19) 3, and Z = 4), space groups, respectively. In both PYRA-1 and PYRA-2 compounds, C-H···O intermolecular connections are common to stabilize the crystal structure. In addition, short intermolecular interactions stabilizes with C-H···π and π-π stacking. Crystal packing analysis was quantified using Hirshfeld surface analysis resulting in C···H, O···H, and H···H contacts in PYRA-1 exhibiting more contribution than in PYRA-2. The conformational stabilities of the molecules are same in the gas and liquid phases (water and DMSO). The docking scores measured for PYRA-1 and PYRA-2 with CDC7 kinase complexes are -5.421 and -5.884 kcal/mol, respectively. The MD simulations show that PYRA-2 is a more potential inhibitor than PYRA-1 against CDC7 kinase.
Collapse
Affiliation(s)
- Mohanbabu Mookkan
- Department
of Physics, Presidency College (Autonomous), University of Madras, Chennai 600 005, India
| | - Saravanan Kandasamy
- Faculty
of Chemistry, University of Warsaw, Ludwika Pasteura 1, Warsaw 02-093, Poland
| | - Abdel-Basit Al-Odayni
- Department
of Restorative Dental Science, College of Dentistry, King Saud University, P.O. Box 60169, Riyadh 11545, Saudi Arabia
| | - Naaser Ahmed Yaseen Abduh
- Department
of Chemistry, College of Science, King Saud
University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
| | - Sugarthi Srinivasan
- Department
of Physics and Nanotechnology, SRM Institute
of Science and Technology, Kattankulathur 603203, India
| | - Bistuvalli Chandrashekara Revannasidappa
- Department
of Pharmaceutical Chemistry, NGSM Institute
of Pharmaceutical Sciences of Nitte - Deemed to be University, Paneer, Deralakatte, Mangalore 575018, Karnataka India
| | - Vasantha Kumar
- Department
of P.G. Chemistry, Sri Dharmasthala Manjunatheshwara
College (Autonomous), Ujire 574240, India
| | | | - Sanmargam Aravindhan
- Department
of Physics, Presidency College (Autonomous), University of Madras, Chennai 600 005, India
| | - Madan Kumar Shankar
- Department
of Chemistry-BMC, University of Uppsala, Husargatan 3, Uppsala 75237, Sweden
| |
Collapse
|
2
|
Marek L, Váňa J, Svoboda J, Hanusek J. Eschenmoser coupling reactions starting from primary thioamides. When do they work and when not? Beilstein J Org Chem 2023; 19:808-819. [PMID: 37346496 PMCID: PMC10280059 DOI: 10.3762/bjoc.19.61] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 05/26/2023] [Indexed: 06/23/2023] Open
Abstract
Reactions of thiobenzamide or thioacetamide with 4-bromo-1,1-dimethyl-1,4-dihydroisoquinoline-3(2H)-one, 4-bromoisoquinoline-1,3(2H,4H)-dione and two α-bromo(phenyl)acetamides were examined under various conditions (base, solvent, thiophile, temperature) and structure/medium features that influence product distribution (Eschenmoser coupling reaction, Hantzsch thiazole synthesis and elimination to nitriles) were identified. The key factor that enables the successful Eschenmoser coupling reaction involves the optimum balance in acidity of nitrogen and carbon atoms of the intermediary α-thioiminium salts.
Collapse
Affiliation(s)
- Lukáš Marek
- Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, CZ532 10 Pardubice, Czech Republic
| | - Jiří Váňa
- Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, CZ532 10 Pardubice, Czech Republic
| | - Jan Svoboda
- Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, CZ532 10 Pardubice, Czech Republic
| | - Jiří Hanusek
- Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, CZ532 10 Pardubice, Czech Republic
| |
Collapse
|
3
|
Song F, Sun H, Ma X, Wang W, Luan M, Zhai H, Su G, Liu Y. QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease. Front Pharmacol 2023; 14:1185004. [PMID: 37266150 PMCID: PMC10230167 DOI: 10.3389/fphar.2023.1185004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 04/18/2023] [Indexed: 06/03/2023] Open
Abstract
Background: Severe acute respiratory syndrome coronavirus (SARS-CoVs) have emerged as a global health threat, which had caused a high rate of mortality. There is an urgent need to find effective drugs against these viruses. Objective: This study aims to predict the activity of unsymmetrical aromatic disulfides by constructing a QSAR model, and to design new compounds according to the structural and physicochemical attributes responsible for higher activity towards SARS-CoVs main protease. Methods: All molecules were constructed in ChemOffice software and molecular descriptors were calculated by CODESSA software. A regression-based linear heuristic method was established by changing descriptors datasets and calculating predicted IC50 values of compounds. Then, some new compounds were designed according to molecular descriptors from the heuristic method model. The compounds with predicted values smaller than a set point were constantly screened out. Finally, the properties analysis and molecular docking were conducted to further understand the structure-activity relationships of these finalized compounds. Results: The heuristic method explored the various descriptors responsible for bioactivity and gained the best linear model with R2 0.87. The success of the model fully passed the testing set validation, proving that the model has both high statistical significance and excellent predictive ability. A total of 5 compounds with ideal predicted IC50 were found from the 96 newly designed derivatives and their properties analyze was carried out. Molecular docking experiments were conducted for the optimal compound 31a, which has the best compound activity with good target protein binding capability. Conclusion: The heuristic method was quite reliable for predicting IC50 values of unsymmetrical aromatic disulfides. The present research provides meaningful guidance for further exploration of the highly active inhibitors for SARS-CoVs.
Collapse
Affiliation(s)
- Fucheng Song
- Qingdao Municipal Center for Disease Control and Prevention, Qingdao, China
| | - Haoyang Sun
- Department of Traditional Chinese Medicine, Songshan Hospital of Qingdao University, Qingdao, China
| | - Xiaofang Ma
- Qingdao Municipal Center for Disease Control and Prevention, Qingdao, China
| | - Wei Wang
- Qingdao Municipal Center for Disease Control and Prevention, Qingdao, China
| | | | - Honglin Zhai
- Department of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China
| | - Guanmin Su
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Yantao Liu
- Qingdao Municipal Center for Disease Control and Prevention, Qingdao, China
| |
Collapse
|
4
|
Kumar Y, Ila H. Domino Synthesis of Thiazolo-Fused Six- and Seven-Membered Nitrogen Heterocycles via Intramolecular Heteroannulation of In-Situ-Generated 2-(Het)aryl-4-amino-5-functionalized Thiazoles. J Org Chem 2022; 87:12397-12413. [PMID: 36069522 DOI: 10.1021/acs.joc.2c01673] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Synthesis of novel 2-(het)aryl-substituted thiazolo-fused six- and seven-membered heterocycles, such as thiazolo[4,5-b]pyridin-5(4H)-ones, thiazolo[4,5-c]isoquinolin-5(4H)-ones, thiazolo[4,5-b]quinolin-9(4H)-ones, 4H-benzo[e]thiazolo[4,5-b]azepine-5,10-diones, have been developed in a single-pot operation via intramolecular heteroannulation of in-situ-generated 2-(het)aryl-4-amino-5-functionalized thiazoles. These 4-amino-5-functionalized thiazoles were readily obtained in a one-pot process by treatment of a range of (het)aryldithioesters with cyanamide in the presence of NaH, followed by in situ S-alkylation-intramolecular condensations of the resulting thioimidate salts with appropriate activated methylene halides. On the other hand, the corresponding 4H-benzo[b]thiazolo[4,5-e][1,4]diazepin-10(9H)-ones were synthesized in a two-step process, requiring prior isolation of 5-carboethoxy-4-(2-nitrophenyl)aminothiazoles and their subsequent reductive cyclization. The activated methylene halides employed in these reactions for the synthesis of various thiazolo-fused heterocycles were methyl bromocrotonate, ethyl 2-(bromomethyl)benzoate, 2-fluorophenacyl bromides, ethyl 2-(2-bromoacetyl)benzoate, and ethyl bromoacetate. Several of these thiazolo-fused heterocycles display yellow green to green fluorescence, and their absorption and emission spectra have also been examined.
Collapse
Affiliation(s)
- Yogendra Kumar
- New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| | - Hiriyakkanavar Ila
- New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| |
Collapse
|
5
|
Chen L, Xuchen X, Wang F, Yang Y, Deng G, Liu Y, Liang Y. Double C-S bond formation via multiple Csp 3-H bond cleavage: synthesis of 4-hydroxythiazoles from amides and elemental sulfur under metal-free conditions. Org Biomol Chem 2021; 19:10068-10072. [PMID: 34762083 DOI: 10.1039/d1ob01989a] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A novel and efficient approach for the synthesis of 4-hydroxythiazoles from amides and elemental sulfur has been developed. In the presence of P2O5, DMSO and HMPA, this metal-free protocol proceeds smoothly and tolerates a spectrum of functional groups. Furthermore, this strategy involves the process of double Csp3-S bond formation through the cleavage of multiple Csp3-H bonds for the first time.
Collapse
Affiliation(s)
- Liang Chen
- National & Local Joint Engineering Laboratory for New Petro-chemical Materials and Fine Utilization of Resources, Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of Education, Key Laboratory of the Assembly and Application of Organic Functional Molecules of Hunan Province, Hunan Normal University, Changsha, Hunan 410081, China. .,Huaihua Normal College, Huaihua 418008, China
| | - Xinyu Xuchen
- National & Local Joint Engineering Laboratory for New Petro-chemical Materials and Fine Utilization of Resources, Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of Education, Key Laboratory of the Assembly and Application of Organic Functional Molecules of Hunan Province, Hunan Normal University, Changsha, Hunan 410081, China.
| | - Fei Wang
- National & Local Joint Engineering Laboratory for New Petro-chemical Materials and Fine Utilization of Resources, Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of Education, Key Laboratory of the Assembly and Application of Organic Functional Molecules of Hunan Province, Hunan Normal University, Changsha, Hunan 410081, China.
| | - Yuan Yang
- National & Local Joint Engineering Laboratory for New Petro-chemical Materials and Fine Utilization of Resources, Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of Education, Key Laboratory of the Assembly and Application of Organic Functional Molecules of Hunan Province, Hunan Normal University, Changsha, Hunan 410081, China.
| | - Guobo Deng
- National & Local Joint Engineering Laboratory for New Petro-chemical Materials and Fine Utilization of Resources, Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of Education, Key Laboratory of the Assembly and Application of Organic Functional Molecules of Hunan Province, Hunan Normal University, Changsha, Hunan 410081, China. .,Ministry of Education Key Laboratory of Functional Molecular Solids, Ministry of Education, Anhui Laboratory of Molecule-Based Materials (State Key Laboratory Cultivation Base), College of Chemistry and Materials Science, Anhui Normal University, Wuhu 241002, P. R. China
| | - Yilin Liu
- Institute of Organic Synthesis, College of Chemistry and Materials Engineering, Huaihua University, Huaihua 418008, China.
| | - Yun Liang
- National & Local Joint Engineering Laboratory for New Petro-chemical Materials and Fine Utilization of Resources, Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of Education, Key Laboratory of the Assembly and Application of Organic Functional Molecules of Hunan Province, Hunan Normal University, Changsha, Hunan 410081, China.
| |
Collapse
|
6
|
Filho EV, Pinheiro EM, Pinheiro S, Greco SJ. Aminopyrimidines: Recent synthetic procedures and anticancer activities. Tetrahedron 2021. [DOI: 10.1016/j.tet.2021.132256] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
7
|
Iwai K, Nambu T, Kashima Y, Yu J, Eng K, Miyamoto K, Kakoi K, Gotou M, Takeuchi T, Kogame A, Sappal J, Murai S, Haeno H, Kageyama SI, Kurasawa O, Niu H, Kannan K, Ohashi A. A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. SCIENCE ADVANCES 2021; 7:7/21/eabf0197. [PMID: 34020950 PMCID: PMC8139593 DOI: 10.1126/sciadv.abf0197] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 04/01/2021] [Indexed: 05/10/2023]
Abstract
Cell division cycle 7 (CDC7), a serine/threonine kinase, plays important roles in DNA replication. We developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. This study aimed to identify the potential combination partners of TAK-931 for guiding its clinical development strategies. Unbiased high-throughput chemical screening revealed that the highest synergistic antiproliferative effects observed were the combinations of DNA-damaging agents with TAK-931. Functional phosphoproteomic analysis demonstrated that TAK-931 suppressed homologous recombination repair activity, delayed recovery from double-strand breaks, and led to accumulation of DNA damages in the combination. Whole-genome small interfering RNA library screening identified sensitivity-modulating molecules, which propose the experimentally predicted target cancer types for the combination, including pancreatic, esophageal, ovarian, and breast cancers. The efficacy of combination therapy in these cancer types was preclinically confirmed in the corresponding primary-derived xenograft models. Thus, our findings would be helpful to guide the future clinical strategies for TAK-931.
Collapse
Affiliation(s)
- Kenichi Iwai
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Tadahiro Nambu
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Yukie Kashima
- Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan
- Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan
| | - Jie Yu
- Oncology Drug Discovery Unit, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
| | - Kurt Eng
- Oncology Drug Discovery Unit, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
| | - Kazumasa Miyamoto
- Integrated Research Laboratory, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Kazuyo Kakoi
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Masamitsu Gotou
- Integrated Research Laboratory, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Toshiyuki Takeuchi
- DMPK Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Akifumi Kogame
- DMPK Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Jessica Sappal
- Oncology Drug Discovery Unit, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
| | - Saomi Murai
- Integrated Biology Oncology, Axcelead Drug Discovery Partners Inc., Fujisawa, Japan
| | - Hiroshi Haeno
- Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan
| | - Shun-Ichiro Kageyama
- Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan
| | - Osamu Kurasawa
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Huifeng Niu
- Oncology Translational Science, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
| | - Karuppiah Kannan
- Oncology Drug Discovery Unit, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
- Oncology Therapeutic Area Unit, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
| | - Akihiro Ohashi
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
- Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan
- Oncology Drug Discovery Unit, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
| |
Collapse
|
8
|
Zhang Z, Shu B, Zhang Y, Deora GS, Li QS. 2,4,5-Trisubstituted Thiazole: A Privileged Scaffold in Drug Design and Activity Improvement. Curr Top Med Chem 2020; 20:2535-2577. [DOI: 10.2174/1568026620999200917153856] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 05/27/2020] [Accepted: 06/05/2020] [Indexed: 11/22/2022]
Abstract
Thiazole is an important 5-membered heterocyclic compound containing nitrogen and sulfur
atoms with various pharmaceutical applications including anti-inflammatory, anti-cancer, anti-viral, hypoglycemic,
anti-bacterial and anti-fungal activities. Until now, the FDA-approved drugs containing thiazole
moiety have achieved great success such as dasatinib and dabrafenib. In recent years, considerable
research has been focused on thiazole derivatives, especially 2,4,5-trisubstituted thiazole derivatives,
due to their multiple medicinal applications. This review covers related literature in the past 20 years,
which reported the 2,4,5-trisubstituted thiazole as a privileged scaffold in drug design and activity improvement.
Moreover, this review aimed to provide greater insights into the rational design of more potent
pharmaceutical molecules based on 2,4,5-trisubstituted thiazole in the future.
Collapse
Affiliation(s)
- Zhen Zhang
- School of Food and Biological Engineering, Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, Hefei University of Technology, Hefei, Anhui, 230601, China
| | - Bing Shu
- Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China
| | - Yaodong Zhang
- Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, 450018, China
| | - Girdhar Singh Deora
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Qing-Shan Li
- School of Food and Biological Engineering, Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, Hefei University of Technology, Hefei, Anhui, 230601, China
| |
Collapse
|
9
|
Zhao Y, Liu X, Ouyang J, Wang Y, Xu S, Tian D, Si H. Studies on the IC50 of Metabolically Stable 1-(3,3-diphenylpropyl)- piperidinyl Amides and Ureas as Human CCR5 Receptor Antagonists Based on QSAR. LETT DRUG DES DISCOV 2020. [DOI: 10.2174/1570180817666200320105725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
In this study, modulators of human Chemotactic cytokine receptor 5
(CCR5) were described using a quantitative structure-activity relationship model (QSAR). This
model was based on the molecule’s chemical structure.
Methods::
All 56 compounds of CCR5 receptor antagonists were randomly separated into two sets,
43 were reserved for training and the other 13 for testing. In the course of this study, molecular
models were drawn using ChemDraw software. By means of Hyperchem software as well as optimized
with both AM1 (semi-empirical self-consistent-field molecular orbital) and MM+ (molecular
mechanics plus force field), molecular models were described through numerous descriptors using
CODESSA software.
Results:
Linear models were obtained by Heuristic Method (HM) software and nonlinear models
were obtained using APS software with optimal descriptor combinations used to build linear QSAR
models, involving a group of selected descriptors. As a result, values of the above two different sets
were shown to result from 0.82 in testing and 0.86 in training in HM while 0.83 in testing and 0.88
in training in Gene Expression Programming (GEP).
Conclusion:
From this method, the activity of molecules could be predicted, and the molecular
structure could be changed to alter its IC50, avoiding the testing of large numbers of compounds.
Collapse
Affiliation(s)
- Yutao Zhao
- School of Public Health, Qingdao University, Qingdao, 266071, China
| | - Xiaoqian Liu
- School of Public Health, Qingdao University, Qingdao, 266071, China
| | - Jing Ouyang
- School of Public Health, Qingdao University, Qingdao, 266071, China
| | - Yan Wang
- School of Public Health, Qingdao University, Qingdao, 266071, China
| | - Shanyu Xu
- School of Stomatology, Qingdao University, Qingdao, 266071, China
| | - Dongdong Tian
- School of Public Health, Qingdao University, Qingdao, 266071, China
| | - Hongzong Si
- Institute for Computational Science and Engineering, Qingdao University, Qingdao, 266071, China
| |
Collapse
|
10
|
Thiazole-containing compounds as therapeutic targets for cancer therapy. Eur J Med Chem 2019; 188:112016. [PMID: 31926469 DOI: 10.1016/j.ejmech.2019.112016] [Citation(s) in RCA: 163] [Impact Index Per Article: 32.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 12/20/2019] [Accepted: 12/26/2019] [Indexed: 12/13/2022]
Abstract
In the last few decades, considerable progress has been made in anticancer agents development, and several new anticancer agents of natural and synthetic origin have been produced. Among heterocyclic compounds, thiazole, a 5-membered unique heterocyclic motif containing sulphur and nitrogen atoms, serves as an essential core scaffold in several medicinally important compounds. Thiazole nucleus is a fundamental part of some clinically applied anticancer drugs, such as dasatinib, dabrafenib, ixabepilone, patellamide A, and epothilone. Recently, thiazole-containing compounds have been successfully developed as possible inhibitors of several biological targets, including enzyme-linked receptor(s) located on the cell membrane, (i.e., polymerase inhibitors) and the cell cycle (i.e., microtubular inhibitors). Moreover, these compounds have been proven to exhibit high effectiveness, potent anticancer activity, and less toxicity. This review presents current research on thiazoles and elucidates their biological importance in anticancer drug discovery. The findings may aid researchers in the rational design of more potent and bio-target specific anticancer drug molecules.
Collapse
|
11
|
Jadhav BS, Yamgar RS, Kenny RS, Mali SN, Chaudhari HK, Mandewale MC. Synthesis, In silico and Biological Studies of Thiazolyl-2h-chromen-2-one Derivatives as Potent Antitubercular Agents. Curr Comput Aided Drug Des 2019; 16:511-522. [PMID: 31438831 DOI: 10.2174/1386207322666190722162100] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2019] [Revised: 05/26/2019] [Accepted: 06/28/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND A series of new six thiazolyl-2-amine-based Schiff base derivatives (4a-4f) were synthesized by a sequential multistep reaction starting with Salicylaldehyde. METHODS All the Schiff base derivatives were screened in-vitro for their antibacterial activity against Mycobacterium tuberculosis (H37RV strain) ATCC No-27294. The synthesized compounds were characterized by FTIR, 1H-NMR, 13C-NMR and Mass spectrometry. RESULTS Among the compounds tested, 4c and 4f derivatives exhibited potent antitubercular activity against M. tuberculosis at MIC 6.25 μg/mL. CONCLUSION We extended our study to explore the inhibition mechanism by conducting molecular docking analysis by using Schrodinger's molecular modeling software. All the newly synthesized compounds were found to be in-silico AMES test non-toxic and non-carcinogens. The good Qikprop's Absorption, Distribution, Metabolism and Excretion (ADMET) would definitely help the researchers in order to make more potent Anti-TB agents.
Collapse
Affiliation(s)
- Bhagwat S Jadhav
- Department of Chemistry, Government of Maharashtra, Ismail Yusuf College of Arts, Science and Commerce, Jogeshwari (East), Mumbai-400 060, India
| | - Ramesh S Yamgar
- Department of Chemistry, Chikitsak Samuha’s Patkar-Varde College of Arts, Science and Commerce, Goregaon (West), Mumbai 400 062, India
| | - Rajesh S Kenny
- Department of Chemistry, Chikitsak Samuha’s Patkar-Varde College of Arts, Science and Commerce, Goregaon (West), Mumbai 400 062, India
| | - Suraj N Mali
- Institute of Chemical Technology, Matunga, Mumbai 400019, India
| | | | - Mustapha C Mandewale
- Department of Chemistry, Government of Maharashtra, Ismail Yusuf College of Arts, Science and Commerce, Jogeshwari (East), Mumbai-400 060, India
| |
Collapse
|
12
|
Iwai K, Nambu T, Dairiki R, Ohori M, Yu J, Burke K, Gotou M, Yamamoto Y, Ebara S, Shibata S, Hibino R, Nishizawa S, Miyazaki T, Homma M, Oguro Y, Imada T, Cho N, Uchiyama N, Kogame A, Takeuchi T, Kurasawa O, Yamanaka K, Niu H, Ohashi A. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. SCIENCE ADVANCES 2019; 5:eaav3660. [PMID: 31131319 PMCID: PMC6531005 DOI: 10.1126/sciadv.aav3660] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 04/17/2019] [Indexed: 05/02/2023]
Abstract
Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell division cycle 7 (CDC7) has recently attracted attention as a target. We have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug. TAK-931 induced S phase delay and RS. TAK-931-induced RS caused mitotic aberrations through centrosome dysregulation and chromosome missegregation, resulting in irreversible antiproliferative effects in cancer cells. TAK-931 exhibited significant antiproliferative activity in preclinical animal models. Furthermore, in indication-seeking studies using large-scale cell panel data, TAK-931 exhibited higher antiproliferative activities in RAS-mutant versus RAS-wild-type cells; this finding was confirmed in pancreatic patient-derived xenografts. Comparison analysis of cell panel data also demonstrated a unique efficacy spectrum for TAK-931 compared with currently used chemotherapeutic drugs. Our findings help to elucidate the molecular mechanisms for TAK-931 and identify potential target indications.
Collapse
Affiliation(s)
- Kenichi Iwai
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Tadahiro Nambu
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Ryo Dairiki
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Momoko Ohori
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Jie Yu
- Oncology Drug Discovery Unit, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Kristine Burke
- Oncology Drug Discovery Unit, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Masamitsu Gotou
- Integrated Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Yukiko Yamamoto
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Shunsuke Ebara
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Sachio Shibata
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Ryosuke Hibino
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Satoru Nishizawa
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Tohru Miyazaki
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Misaki Homma
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Yuya Oguro
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Takashi Imada
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Nobuo Cho
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Noriko Uchiyama
- Biomolecular Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Akifumi Kogame
- DMPK Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Toshiyuki Takeuchi
- DMPK Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Osamu Kurasawa
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Kazunori Yamanaka
- Integrated Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Huifeng Niu
- Translational and Biomarker Research, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Akihiro Ohashi
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
- Oncology Drug Discovery Unit, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
- Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan
- Corresponding author.
| |
Collapse
|
13
|
Cheng AN, Lo YK, Lin YS, Tang TK, Hsu CH, Hsu JTA, Lee AYL. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach. EBioMedicine 2018; 36:241-251. [PMID: 30293817 PMCID: PMC6197782 DOI: 10.1016/j.ebiom.2018.09.030] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Revised: 09/16/2018] [Accepted: 09/17/2018] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Cdc7-Dbf4 is a conserved serine/threonine kinase that plays an important role in initiation of DNA replication and DNA damage tolerance in eukaryotic cells. Cdc7 has been found overexpressed in human cancer cell lines and tumor tissues, and the knockdown of Cdc7 expression causes an p53-independent apoptosis, suggesting that Cdc7 is a target for cancer therapy. Only a handful Cdc7 kinase inhibitors have been reported. All Cdc7 kinase inhibitors, including PHA-767491, were identified and characterized as ATP-competitive inhibitors. Unfortunately, these ATP-competitive Cdc7 inhibitors have no good effect on clinical trial. METHODS Here, we have developed a novel drug-screening platform to interrupt the interaction between Cdc7 and Dbf4 based on Renilla reniformis luciferase (Rluc)-linked protein-fragment complementation assay (Rluc-PCA). Using drug repositioning approach, we found several promising Cdc7 inhibitors for cancer therapy from a FDA-approved drug library. FINDINGS Our data showed that dequalinium chloride and clofoctol we screened inhibit S phase progression, accumulation in G2/M phase, and Cdc7 kinase activity. In addition, in vivo mice animal study suggests that dequalinium chloride has a promising anti-tumor activity in oral cancer. Interestingly, we also found that dequalinium chloride and clofoctol sensitize the effect of platinum compounds and radiation due to synergistic effect. In conclusion, we identified non-ATP-competitive Cdc7 kinase inhibitors that not only blocks DNA synthesis at the beginning but also sensitizes cancer cells to DNA damage agents. INTERPRETATION The inhibitors will be a promising anti-cancer agent and enhance the therapeutic effect of chemotherapy and radiation for current cancer therapy. FUND: This work was supported by grants from the Ministry of Science and Technology, Ministry of Health and Welfare, and National Health Research Institutes, Taiwan.
Collapse
Affiliation(s)
- An Ning Cheng
- National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan
| | - Yu-Kang Lo
- National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan
| | - Yi-Sheng Lin
- National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan
| | - Tswen-Kei Tang
- Department of Nursing, National Quemoy University, Kinmen 89250, Taiwan
| | - Chun-Hua Hsu
- Genome and Systems Biology Degree Program, National Taiwan University and Academia Sinica, Taipei 10617, Taiwan; Department of Agricultural Chemistry, National Taiwan University, Taipei 10617, Taiwan
| | - John T-A Hsu
- National Health Research Institutes, Institute of Biotechnology and Pharmaceutical Research, Miaoli 35053, Taiwan
| | - Alan Yueh-Luen Lee
- National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan; Department of Biotechnology, College of Life Science, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
| |
Collapse
|
14
|
Fei L, Xu H. Role of MCM2-7 protein phosphorylation in human cancer cells. Cell Biosci 2018; 8:43. [PMID: 30062004 PMCID: PMC6056998 DOI: 10.1186/s13578-018-0242-2] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Accepted: 07/17/2018] [Indexed: 01/12/2023] Open
Abstract
A heterohexameric complex composed of minichromosome maintenance protein 2–7 (MCM2–7), which acts as a key replicative enzyme in eukaryotes, is crucial for initiating DNA synthesis only once per cell cycle. The MCM complex remains inactive through the G1 phase, until the S phase, when it is activated to initiate replication. During the transition from the G1 to S phase, the MCM undergoes multisite phosphorylation, an important change that promotes subsequent assembly of other replisome members. Phosphorylation is crucial for the regulation of MCM activity and function. MCMs can be phosphorylated by multiple kinases and these phosphorylation events are involved not only in DNA replication but also cell cycle progression and checkpoint response. Dysfunctional phosphorylation of MCMs appears to correlate with the occurrence and development of cancers. In this review, we summarize the currently available data regarding the regulatory mechanisms and functional consequences of MCM phosphorylation and seek the probability that protein kinase inhibitor can be used therapeutically to target MCM phosphorylation in cancer.
Collapse
Affiliation(s)
- Liangru Fei
- Department of Pathology, College of Basic Medical Sciences and the First Affiliated Hospital, China Medical University, No.77 Puhe Road, Shenyang North New Area, Shenyang, 110122 Liaoning Province People's Republic of China
| | - Hongtao Xu
- Department of Pathology, College of Basic Medical Sciences and the First Affiliated Hospital, China Medical University, No.77 Puhe Road, Shenyang North New Area, Shenyang, 110122 Liaoning Province People's Republic of China
| |
Collapse
|
15
|
Jiang XY, Chen TK, Zhou JT, He SY, Yang HY, Chen Y, Qu W, Feng F, Sun HP. Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery. ACS Med Chem Lett 2018. [PMID: 29541355 DOI: 10.1021/acsmedchemlett.7b00463] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer's disease (AD). The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3β (GSK-3β) and human acetylcholinesterase (hAChE), might represent a breakthrough in the quest for clinical efficacy. Thus, a novel family of GSK-3β/AChE dual-target inhibitors was designed and synthesized. Among these hybrids, 2f showed the most promising profile as a nanomolar inhibitor on both hAChE (IC50 = 6.5 nM) and hGSK-3β kinase activity (IC50 = 66 nM). It also showed good inhibitory effect on β-amyloid self-aggregation (inhibitory rate = 46%) at 20 μM. Western blot analysis revealed that compound 2f inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells. In vivo studies confirmed that 2f significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine. This study provides new leads for assessment of GSK-3β and AChE pathway dual inhibition as a promising strategy for AD treatment.
Collapse
Affiliation(s)
- Xue-Yang Jiang
- Department of Natural Medicinal Chemistry and ‡Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
| | - Ting-Kai Chen
- Department of Natural Medicinal Chemistry and ‡Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
| | - Jun-Ting Zhou
- Department of Natural Medicinal Chemistry and ‡Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
| | | | | | - Yao Chen
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
| | - Wei Qu
- Department of Natural Medicinal Chemistry and ‡Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
| | - Feng Feng
- Department of Natural Medicinal Chemistry and ‡Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
| | | |
Collapse
|
16
|
Ahmed Arafa WA, Ibrahim HM. A sustainable strategy for the synthesis of bis-2-iminothiazolidin-4-ones utilizing novel series of asymmetrically substituted bis-thioureas as viable precursors. RSC Adv 2018; 8:10516-10521. [PMID: 35540444 PMCID: PMC9078912 DOI: 10.1039/c8ra01253a] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 03/01/2018] [Indexed: 01/17/2023] Open
Abstract
A series of bis-thioureas was synthesized as viable precursors for the design of bis-2-iminothiazolidin-4-ones utilizing the ultrasonic irradiation as a sustainable energy source.
Collapse
|
17
|
Microwave-assisted one pot synthesis, characterization, biological evaluation and molecular docking studies of steroidal thiazoles. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY 2017; 166:104-115. [DOI: 10.1016/j.jphotobiol.2016.11.010] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/01/2016] [Accepted: 11/11/2016] [Indexed: 11/20/2022]
|
18
|
Bueno JM, Carda M, Crespo B, Cuñat AC, de Cozar C, León ML, Marco JA, Roda N, Sanz-Cervera JF. Design, synthesis and antimalarial evaluation of novel thiazole derivatives. Bioorg Med Chem Lett 2016; 26:3938-44. [PMID: 27432764 DOI: 10.1016/j.bmcl.2016.07.010] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 07/01/2016] [Accepted: 07/04/2016] [Indexed: 11/25/2022]
Abstract
As part of our medicinal chemistry program's ongoing search for compounds with antimalarial activity, we prepared a series of thiazole analogs and conducted a SAR study analyzing their in vitro activities against the chloroquine-sensitive Plasmodium falciparum 3D7 strain. The results indicate that modifications of the N-aryl amide group linked to the thiazole ring are the most significant in terms of in vitro antimalarial activity, leading to compounds with high antimalarial potency and low cytotoxicity in HepG2 cell lines. Furthermore, the observed SAR implies that non-bulky, electron-withdrawing groups are preferred at ortho position on the phenyl ring, whereas small atoms such as H or F are preferred at para position. Finally, replacement of the phenyl ring by a pyridine affords a compound with similar potency, but with potentially better physicochemical properties which could constitute a new line of research for further studies.
Collapse
Affiliation(s)
- José María Bueno
- Tres Cantos Medicines Development Campus, DDW, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Miguel Carda
- Departamento de Química Inorgánica y Orgánica, Univ. Jaume I, 12071 Castellón, Spain
| | - Benigno Crespo
- Tres Cantos Medicines Development Campus, DDW, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Ana Carmen Cuñat
- Departamento de Química Orgánica, Facultad de Química, Univ. de València, Calle Dr. Moliner 50, 46100 Burjassot, Spain.
| | - Cristina de Cozar
- Tres Cantos Medicines Development Campus, DDW, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - María Luisa León
- Tres Cantos Medicines Development Campus, DDW, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain.
| | - J Alberto Marco
- Departamento de Química Orgánica, Facultad de Química, Univ. de València, Calle Dr. Moliner 50, 46100 Burjassot, Spain
| | - Nuria Roda
- Departamento de Química Orgánica, Facultad de Química, Univ. de València, Calle Dr. Moliner 50, 46100 Burjassot, Spain
| | - Juan F Sanz-Cervera
- Departamento de Química Orgánica, Facultad de Química, Univ. de València, Calle Dr. Moliner 50, 46100 Burjassot, Spain
| |
Collapse
|
19
|
Bondock S, Albormani O, Fouda AM, Abu Safieh KA. Progress in the chemistry of 5-acetylthiazoles. SYNTHETIC COMMUN 2016. [DOI: 10.1080/00397911.2016.1180700] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Samir Bondock
- Chemistry Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia
- Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Omeer Albormani
- Chemistry Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia
| | - Ahmed M. Fouda
- Chemistry Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia
| | - Kayed A. Abu Safieh
- Chemistry Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia
| |
Collapse
|
20
|
Cui LY, Wang YM, Zhou ZH. Enantioselective construction of novel chiral spirooxindoles incorporating a thiazole nucleus. RSC Adv 2016. [DOI: 10.1039/c6ra14178a] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Enantioselective synthesis of novel thiazole-fused spirooxindoles has been realized via chiral thiourea catalyzed asymmetric cascade Michael addition/cyclization of thiazolones and 3-ylideneoxindoles.
Collapse
Affiliation(s)
- L.-Y. Cui
- Institute and State Key Laboratory of Elemento-Organic Chemistry
- Nankai University
- Tianjin 300071
- P. R. China
| | - Y.-M. Wang
- Institute and State Key Laboratory of Elemento-Organic Chemistry
- Nankai University
- Tianjin 300071
- P. R. China
| | - Z.-H. Zhou
- Institute and State Key Laboratory of Elemento-Organic Chemistry
- Nankai University
- Tianjin 300071
- P. R. China
- Collaborative Innovation Center of Chemical Science and Engineering (Tianjin)
| |
Collapse
|
21
|
Balasubramanian PK, Balupuri A, Cho SJ. Molecular Modeling Studies of Trisubstituted Thiazoles as Cdc7 Kinase Inhibitors through 3D-QSAR and Molecular Docking Simulation. B KOREAN CHEM SOC 2015. [DOI: 10.1002/bkcs.10304] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Pavithra K. Balasubramanian
- Department of Bio-New Drug Development, College of Medicine; Chosun University; Gwangju 501-759 Republic of Korea
| | - Anand Balupuri
- Department of Bio-New Drug Development, College of Medicine; Chosun University; Gwangju 501-759 Republic of Korea
| | - Seung Joo Cho
- Department of Bio-New Drug Development, College of Medicine; Chosun University; Gwangju 501-759 Republic of Korea
- Department of Cellular Molecular Medicine, College of Medicine; Chosun University; Gwangju 501-759 Republic of Korea
| |
Collapse
|
22
|
Ayati A, Emami S, Asadipour A, Shafiee A, Foroumadi A. Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery. Eur J Med Chem 2015; 97:699-718. [PMID: 25934508 DOI: 10.1016/j.ejmech.2015.04.015] [Citation(s) in RCA: 254] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2014] [Revised: 10/26/2014] [Accepted: 04/06/2015] [Indexed: 02/07/2023]
Abstract
1,3-Thiazole is one of the most important scaffolds in heterocyclic chemistry and drug design and discovery. It is widely found in diverse pharmacologically active substances and in some naturally-occurring compounds. Thiazole is a versatile building-block for lead generation, and is easily access of diverse derivatives for subsequent lead optimization. In the recent years, many thiazole derivatives have been synthesized and subjected to varied biological activities. In this article we intended to review the most important biological effects of thiazole-based compounds and highlight their roles in new leads identification and drug discovery. This article is also intended to help researches for finding potential future directions on the development of more potent and specific analogs of thiazole-based compounds for various biological targets.
Collapse
Affiliation(s)
- Adile Ayati
- Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Saeed Emami
- Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
| | - Ali Asadipour
- Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medicinal Sciences, Kerman, Iran
| | - Abbas Shafiee
- Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Alireza Foroumadi
- Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran; Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medicinal Sciences, Kerman, Iran.
| |
Collapse
|